Search

Ion Beam Applications

Închisă

10.54 -1.5

Rezumat

Modificarea prețului

24h

Curent

Minim

10.2

Maxim

10.8

Indicatori cheie

By Trading Economics

Venit

-10M

Vânzări

206M

P/E

Medie Sector

41.111

63.778

Randament dividend

1.56

Marjă de profit

-4.99

Angajați

1,943

EBITDA

-372K

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.56%

2.39%

Statistici piață

By TradingEconomics

Capitalizare de piață

342M

Deschiderea anterioară

12.04

Închiderea anterioară

10.54

Ion Beam Applications Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 sept. 2024, 06:28 UTC

Achiziții, Fuziuni, Preluări

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.